Regeneron Reveals Data from Extended P-III (PULSAR) Trial of Eylea HD for Wet Age-related Macular Degeneration
Shots:
- Regeneron reported 3yr. data from an extension study of P-III (PULSAR) trial of Eylea for wAMD pts, randomized to Eylea HD (8mg; Q3M or Q4M) or Eylea (2mg; Q2M)
- After 2yrs., 88% of Eylea HD patients maintained a dosing interval of ≥3 months, while in 60wk. extension, 77%, 58%, 40% & 24% (out of 375 pts) had a dosing interval of ≥3, ≥4, ≥5, & ≥6mos., respectively. Vision gains & reduced retinal thickness were sustained during 3yr.
- Pts who received Eylea (Q2M for 96wks.) switched to Eylea HD (Q3M) in the extension, where 79%, 43% & 16% (out of 186 pts) maintained a ≥3, ≥4 & ≥5mos. dosing interval, respectively, with sustained vision & anatomical improvements. Data was presented at Angiogenesis 2025
Ref: Regeneron | Image: Regeneron
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
